Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
2–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
active sJIA disease according to ILAR criteria before screening and at baseline (Day 1);
Treatment with stable doses of methotrexate (MTX) ≤25 mg/week or ≤20 mg/m2/week, whichever is lower, is permitted;
Treatment with a stable dose of oral prednisone ≤1 mg/kg/day up to a maximum of 30 mg/day, or equivalent, for at least 1 week before the first study drug dose is permitted.
You may not be if
Previous juvenile idiopathic arthritis (JIA) treatment with tofacitinib.
Current symptoms or findings of myocarditis, endocarditis or more than minimal pericardial effusion associated with systemic juvenile idiopathic arthritis (sJIA). Current symptoms or findings of more than minimal pleuritis with sJIA.
Current infection or serious infection within 3 months of study enrollment.
Clareo Health | A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
